StockData
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) stock

IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.48−0.05 (-0.66%)

Close on Nov 18, 2026Market cap $3.39BP/E –Yield –

Iovance Biotherapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Iovance Biotherapeutics's pe ratio was 4.0× on Jul 31, 2013.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2013Jul 31, 20134.0×–

More Iovance Biotherapeutics figures

See a number that looks wrong?